Abstract
Cytokine release syndrome (CRS) is a condition characterized by an overly aggressive immune response to infection or immunotherapies that can be fatal if left untreated. During CRS white blood cells release interleukin 6 along with other inflammatory cytokines that amplify the body’s inflammatory response. Treatments for CRS often involve the administration of monoclonal antibodies that either bind to IL6 receptors (i.e. Tocilizumab) or to IL6 itself (i.e. Siltuximab), therefore minimizing its signaling effects. While effective at reducing the harmful outcomes of excess IL6, these treatments interfere with immunoassay monitoring of serum IL6 concentrations, making treatment evaluation difficult. To address this clinical need, we developed a sensor array of chemically modified carbon nanotubes wrapped in DNA (OCC-DNAs) that can monitor serum IL6 levels, regardless of administered treatment. The OCC-DNAs with the best sensitivity and specificity for IL6 were evaluated in serum samples from CRS patients with sepsis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
